News

This interview highlights the takeaways from Kircik’s talk at the 2025 RAD Conference regarding JAK inhibitor use and boxed warning concerns.

Brendon Neuen, MBBS, PhD, is joined by Rajiv Agarwal, MD, MS to explore the concept of simultaneous initiation of SGLT2i and nsMRA in CKD and T2D.

Compared to age-matched controls, women with premature menopause had greater risks of all-cause mortality and multiple cardiovascular complications.

Disrupted circadian rest-activity rhythms were tied to faster biological aging in older adults, independent of age, sex, or race, new study shows.

New data from a phase 2 and an OLE trial provide additional insight into the effects of iptacopan in IgA nephropathy.

Richard Lafeyette, MD, discusses his reaction to the phase 3 ORIGIN topline results and what it means for IgAN.

GLP-1 RAs, one of the most common medications for obesity and diabetes, have several inherent risks that are often overlooked in favor of their efficacy.

The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.

Immunization is underused in IBD care despite high infection risks from immunosuppressants—early, proactive vaccination is essential for prevention.

UK study finds atopic conditions, especially anaphylaxis, significantly raise the risk of anxiety, depression, OCD, and other mental illnesses in primary care patients.

This video includes a discussion of different procedures designed to help treat patients with hidradenitis suppurativa (HS) and atopic dermatitis.

Combination therapy with finerenone and empagliflozin significantly reduces urinary albumin levels in CKD patients.

This recent study highlights the intricate variations between glaucoma cases, encouraging a more individual approach to analyzing treatment responses.

Jonathan Barratt, MD, PhD, offers perspective on how the 100-week data from ERA 25 inform the potential of zigakibart.

New 100-week data reveals zigakibart's significant efficacy and safety in reducing proteinuria for IgA nephropathy.

Get an overview of the top stories from May 2025 in endocrinology in our monthly recap!

Asthma and peanuts were identified as key risk factors for grade 4 anaphylaxis in a retrospective study, highlighting the need for tailored prevention.

Alkhouri reviews data from the trial’s open-label compensated MASH cirrhosis arm demonstrating resmetirom’s impact on liver stiffness and CSPH.

If approved, lamivudine may bring DME treatment and better vision outcomes to communities who cannot afford more costly intravitreal injections.

An overview of the 7 presentations included as late-breaking clinical trials at ERA 2025.

Sciurba shared his excitement for the recent approval of mepolizumab for people with COPD and an eosinophilic phenotype.

These findings were announced by Sagimet Biosciences, showing that denifanstat met each of its primary and secondary endpoints in patients with acne.

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

A recent study reveals no link between cesarean delivery and childhood allergies, challenging previous findings and highlighting Japan's unique health context.

Hosts discuss a consensus repot from the ADA focused on screening and early interview of MASLD in people with diabetes.

A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

Check out these 7 late-breaking abstracts to watch at the upcoming SLEEP 2025 meeting.